Memantina Pensa (Memantine Hydrochloride)

• Memantine Hydrochloride acts on the glutamatergic pathway and is indicated for dementia‑related conditions.
• Alzheimer's disease (moderate to severe): improves cognition and daily functioning in patients with established disease.
• Alzheimer's disease (mild to moderate, as adjunct): may provide modest benefit when combined with a cholinesterase inhibitor.
• Behavioral symptoms of dementia: can reduce agitation and aggression in some patients.

• Memantine Hydrochloride binds to the NMDA (N‑methyl‑D‑aspartate) receptor at a site distinct from the glutamate binding site, acting as a non‑competitive antagonist. By blocking excessive calcium influx through the receptor channel, it reduces excitotoxic neuronal injury that contributes to cognitive decline in Alzheimer’s disease.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Dizziness: transient light‑headedness, especially at treatment initiation.
• Headache: mild to moderate intensity, often resolves with continued therapy.
• Constipation: reduced bowel movements, manageable with diet or laxatives.
• Fatigue: feeling unusually tired or low‑energy.

Serious or Rare Side Effects

• Seizures: rare occurrence, requires immediate medical attention.
• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis: life‑threatening skin reactions.
• Hepatic injury: elevated liver enzymes or jaundice.
• Cardiac arrhythmia: irregular heart rhythm in susceptible individuals.

• Before initiating therapy, clinicians should evaluate patient‑specific risk factors.
• Renal impairment: dose adjustment may be required in patients with reduced kidney function.
• Hepatic impairment: monitor liver function tests periodically.
• History of seizures: use with caution and observe for new seizure activity.
• Concomitant NMDA antagonists: avoid co‑administration to prevent additive neuro‑toxicity.
• Pregnancy and breastfeeding: safety not established; weigh potential benefits against risks.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with several drug classes; monitoring is advised.

Major Interactions (Avoid)

• Amantadine: additive NMDA antagonism may increase neuro‑psychiatric effects.
• Ketamine: combined NMDA blockade can potentiate central nervous system depression.
• Other NMDA antagonists (e.g., dextromethorphan): risk of excessive inhibition of glutamatergic signaling.

Moderate Interactions (Monitor Closely)

• Anticholinesterase inhibitors: may blunt cognitive benefit; monitor response.
• CNS depressants (e.g., benzodiazepines): increased sedation risk.
• Antihypertensives: possible additive hypotensive effect.
• Diuretics: monitor electrolytes and renal function.
• Anticholinergic agents: may exacerbate confusion or dizziness.